<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621604</url>
  </required_header>
  <id_info>
    <org_study_id>35RC17_9804_REVOLUMHOD</org_study_id>
    <nct_id>NCT04621604</nct_id>
  </id_info>
  <brief_title>Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.</brief_title>
  <acronym>REVOLUMHOD</acronym>
  <official_title>Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-PD-1antibodies (iPD-1) are indicated as monotherapy in the treatment of adult patients&#xD;
      with classical LH. The recommended dosage in LH is based on solid tumour experience and no&#xD;
      dose-concentration-effect studies have been conducted.&#xD;
&#xD;
      According to the literature, therapeutic efficacy appears to be highly variable, and could be&#xD;
      related to differences in treatment exposure.&#xD;
&#xD;
      Since Total metabolic tumor volume (TMTV) is a prognostic factor in LH and the clearance of&#xD;
      iPD-1, and thus exposure to iPD-1, is related to clinical efficacy, we hypothesize that TMTV&#xD;
      influences the exposure to iPD-1 and thus its therapeutic efficacy.&#xD;
&#xD;
      The aim of this study is to evaluate the relationship between TMTV and anti-PD-1 exposure in&#xD;
      refractory or relapsed LH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-PD-1antibodies (iPD-1), nivolumab (NIV) and pembrolizumab (PEM), act by blocking the&#xD;
      interaction of the PD-1 receptor with its PDL1/PDL-2 ligands, which are overexpressed by&#xD;
      tumour cells and their microenvironment, thus restoring an effective anti-tumour response.&#xD;
      NIV and PEM are indicated as monotherapy in the treatment of adult patients with classical&#xD;
      LH. They are administered as intravenous infusions on an outpatient basis. The recommended&#xD;
      dosage for IVN or EMP in LH is based on solid tumour experience and no&#xD;
      dose-concentration-effect studies have been conducted.&#xD;
&#xD;
      According to the literature, therapeutic efficacy appears to be highly variable, and could be&#xD;
      related to differences in treatment exposure.&#xD;
&#xD;
      Since Total metabolic tumor volume (TMTV) is a prognostic factor in LH and the clearance of&#xD;
      iPD-1, and thus exposure to iPD-1, is related to clinical efficacy, we hypothesize that TMTV&#xD;
      influences the exposure to iPD-1 and thus its therapeutic efficacy.&#xD;
&#xD;
      The aim of this study is to evaluate the relationship between TMTV and anti-PD-1 exposure in&#xD;
      refractory or relapsed LH. Highlighting such a relationship will make it possible to identify&#xD;
      treatment algorithms according to the initial TMTV with a target plasma concentration defined&#xD;
      according to the TMTV measurement. New therapeutic biomarkers would thus be highlighted.&#xD;
&#xD;
      This personalised medicine approach would make it possible to maximise the effect while&#xD;
      reducing toxicity. This project is a first step in the implementation of a clinical study&#xD;
      leading to recommendations for anti-PD-1 dose adaptation based on concentration and TMTV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pearson's correlation between the initial Tumour Metabolic Total Volume and the area under the curve of iPD-1 .</measure>
    <time_frame>1 month</time_frame>
    <description>linear relationship, using Pearson's correlation, between the initial Tumour Metabolic Total Volume and the area under the curve (AUC) of iPD-1 during the first treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient at least 18 years of age&#xD;
&#xD;
          -  Patient for whom anti-PD-1 antibody therapy (nivolumab or pembrolizumab) is given as&#xD;
             monotherapy for relapsed or refractory classical Hodgkin's lymphoma within the scope&#xD;
             of the WMA.&#xD;
&#xD;
          -  Patient for whom a PET-CT for the evaluation of TMTV is available within 30 days prior&#xD;
             to the first treatment without intercurrent antitumour therapy between the last PET-CT&#xD;
             and the start of anti-PD1 treatment.&#xD;
&#xD;
          -  For women of childbearing age, use of effective contraception&#xD;
&#xD;
          -  Patient with free, informed and written consent&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons of full age subject to legal protection (judicial protection, guardianship,&#xD;
             trusteeship), persons deprived of their liberty, pregnant or breastfeeding women,&#xD;
             persons unable to give consent&#xD;
&#xD;
          -  Patient with a contraindication to NIV or PEM treatment&#xD;
&#xD;
          -  Patient previously treated with anti-PD1 regardless of indication&#xD;
&#xD;
          -  Patient treated with anti-PD1 in combination with other anti-tumour treatment&#xD;
&#xD;
          -  Patient participating in another interventional clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roch Houot, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Laure Gervais, PhD</last_name>
    <phone>2.99.28.43.21</phone>
    <email>marie-laure.gervais@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Lemaitre, PhD</last_name>
    <phone>2.99.28.43.21</phone>
    <email>florian.lemaitre@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre Moles</last_name>
      <email>mpmoles@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamal-Krimo BOUABDALLAH</last_name>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Tempescul</last_name>
      <email>adrian.tempescul@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Sévigné</name>
      <address>
        <city>Cesson-Sévigné</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HP Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien Le Bras</last_name>
      <email>fabien.le-bras@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René-Olivier Casasnovas</last_name>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHBS Lorient</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Cartron</last_name>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Gastinne</last_name>
      <email>thomas.gastinne@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie Guidez</last_name>
      <email>stephanie.guidez@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH St Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Launay</last_name>
      <email>vincent.launay@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH St Malo</name>
      <address>
        <city>Saint-Malo</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan ERTAULT DE LA BRETONNIERE</last_name>
      <email>m.ertault@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHBA Vannes</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Bonnet</last_name>
      <email>antoine.bonnet@ch-bretagne-atlantique.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

